Why Ascendis Pharma A/S’s (ASND) Stock Is Down 10.27%
As of Tuesday, September 15, Ascendis Pharma A/S’s ASND share price has dipped by 10.27%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Commentary & Analysis
Why Ascendis Pharma A/S’s (ASND) Stock Is Down 12.50%
As of Tuesday, September 15, Ascendis Pharma A/S’s ASND share price has dipped by 12.50%, which has investors questioning if this is right time to buy.Omar Beirat
Why Ascendis Pharma A/S’s (ASND) Stock Is Up 5.76%
As of Monday, August 31, Ascendis Pharma A/S’s ASND share price has surged by 5.76%, which has investors questioning if this is right time to sell.Rosalio Madrigal
What You Need to Know About Ascendis Pharma A/S's Q3 Earnings
Ascendis Pharma A/S's fiscal Q3 earnings report was released on Thursday, August 13. Let's dive in to see if (ASND) missed or beat analyst's expectations.Jenna Brashear
Is Ascendis Pharma A/S (ASND) Overvalued?
We dive into why Ascendis Pharma A/S (ASND) could be considered overvalued on 2026-07-21, based on AAII’s Value Score and Grade.Rosalio Madrigal
Financial Summary
| Share Statistics | ASND | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $15,054.3 | $242.6 | 83% |
|
| Shares Out (Mil) | 78.1 | 54.0 | 57% |
|
| Institutional Ownership | 100.0% | 93.1% | 99% |
|
| Float (Mil) | 65.6 | 41.4 | 53% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 824 | 633 | 66% |
|
| Price Change (52-week) |
na | 50.0% | na |
|
| Growth | ASND | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 150.9% | 12.5% | 99% |
|
| Net Income (5yr) | 12.2% | (10.1%) | 59% |
|
| EPS (5yr) | 15.3% | 15.8% | 58 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 40.3% | (15.7%) | 91% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 5 | 5 | |
| Current EPS | $1.049 | $14.323 | $10.767 | |
| Month Ago EPS | $1.064 | $12.642 | $9.011 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 2 | 1 | |
| Three Months Ago EPS | $1.403 | $13.230 | $10.313 | |
| Year/Year Chg | (67.5%) | (424.2%) | (329.4%) | |
| Financials | ASND | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,196 | $37 | 52% |
|
| Net Income (TTM) (Mil) | $847 | ($44) | 84% |
|
| EPS (TTM) | $13.670 | ($1.600) | 96% |
|
| Operating Cash Flow (TTM) (Mil) | $399 | ($34) | 68% |
|
| Net Cash Flow (TTM) (Mil) | $367 | $2 | 89% |
|
| Long-Term Debt (Q1) (Mil) | $439 | $4 | 57% |
|
| Enterprise Value (Q1) (Mil) | $15,865 | $177 | 81% |
|
| Valuation | ASND | Industry Median |
Percentile (All Stocks) |
|
| P/B | 9.17 | 2.33 | 90% |
|
| P/E | 17.1 | 19.6 | 46% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 1.1 | 1.0 | 51% |
|
| Ratios | ASND | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 91.3% | 67.3% | 94% |
|
| Net Margin | 70.8% | (74.8%) | 98% |
|
| ROA | 43.6% | (47.6%) | 99% |
|
| ROE | 119.3% | (54.9%) | 97% |
|
| Liabilities to Assets | 37.2% | 29.3% | 28% |
|
| F-Score | 7 | 3 | 82% |
|
Ascendis Pharma A/S did not pass any screens on 10/9/2026.
